We determined that a combination of metformin with a lower dose (5 nM) of venetoclax can induce the growth inhibition and metabolic activity of CD34+ chemoresistant AML cells, and these effects can be induced with higher doses of venetoclax as well. Here, CD34 is linked to acute myeloid leukemia.